lorazepam has been researched along with Nausea in 60 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study demonstrated the evidence that promethazine is superior to lorazepam in management of peripheral vertigo and vertigo-related nausea in ED adults." | 9.19 | Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. ( Amini, A; Asadollahi, S; Habibi, T; Heidari, K; Kariman, H; Mansouri, B; Shahrami, A, 2014) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 9.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| "This study was carried out to assess the efficacy of oral lorazepam on postoperative nausea and vomiting in patients undergoing thyroid surgery." | 9.08 | [Prevention of postoperative nausea and vomiting by lorazepam]. ( Benaguida, M; Bouaguad, A; el Mouknia, M; Idali, B; Laraki, M, 1996) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 9.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 9.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 9.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 8.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 7.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "An oral combination of cinnarizine and lorazepam was studied for the prophylaxis of nausea and vomiting induced by strongly emetogenic cancer chemotherapy." | 7.67 | Antiemetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam. ( Senn, HJ; Wilder-Smith, CH, 1989) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 6.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 6.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "A double-blind crossover trial comparing lorazepam at two dosage levels with amylobarbitone supported previous reports of the effective anxiolytic action of the drug." | 6.64 | A comparison of high- and low-dose lorazepam with amylobarbitone in patients with anxiety states. ( McClelland, HA; Newell, DJ; Schapira, K, 1977) |
| "Vomiting was observed in 47/71 patients (66%) and 79/164 cycles (48%)." | 5.51 | Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia. ( Goldman, RD; Hasegawa, D; Kishimoto, K; Kosaka, Y; Ono, A, 2019) |
| "The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting." | 5.19 | A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014) |
| "Our study demonstrated the evidence that promethazine is superior to lorazepam in management of peripheral vertigo and vertigo-related nausea in ED adults." | 5.19 | Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. ( Amini, A; Asadollahi, S; Habibi, T; Heidari, K; Kariman, H; Mansouri, B; Shahrami, A, 2014) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 5.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| "Both metoclopramide and prochlorperazine in combination with lorazepam and diphenhydramine offer good control of nausea and vomiting although the sedation and low risk for cardiac toxicity limit the regimen to an inpatient setting with close monitoring." | 5.08 | Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. ( Gilbert, CJ; Ohly, KV; Peters, WP; Rosner, G, 1995) |
| "This study was carried out to assess the efficacy of oral lorazepam on postoperative nausea and vomiting in patients undergoing thyroid surgery." | 5.08 | [Prevention of postoperative nausea and vomiting by lorazepam]. ( Benaguida, M; Bouaguad, A; el Mouknia, M; Idali, B; Laraki, M, 1996) |
| "This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for chemotherapy-induced nausea and vomiting." | 5.07 | Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. ( Barrett, RJ; Hahne, WF; Heck, K; Homesley, HD; Lentz, SS; Lovelace, JV; McLees, B; Woodlief, L, 1993) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 5.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 5.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 5.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "The present trial was designed to compare the effect of metoclopramide(MCP) + dexamethasone(DM) (Method A) with that of MCP + DM + lorazepam(Lor) (Method B) in the treatment of CDDP (cis-diamminedichloroplatinum)-induced nausea and vomiting in a randomized fashion." | 5.06 | [Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy]. ( Arai, R; Furuse, K; Hayashi, S; Kawahara, M; Kiyota, T; Kodama, N; Tsuruta, S, 1987) |
| "Lorazepam was compared to placebo to assess its control of nausea and vomiting in patients receiving cytotoxic chemotherapy and prochlorperazine." | 5.05 | Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. ( Bingham, J; Bishop, JF; Cooper, IA; Hillcoat, BL; Long, M; Matthews, JP; Olver, IN; Wolf, MM, 1984) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 4.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| " Indications for droperidol included agitation, 68 (86%); nausea/vomiting, 7 (9%); headache, 2 (3%); and other pain, 2 (3%)." | 3.76 | Droperidol use in pediatric emergency department patients. ( Sacchetti, A; Szwak, K, 2010) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 3.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "Lorazepam, dexamethasone and high-dose metoclopramide were given to 54 patients to prevent emesis induced by cisplatin (50-120 mg/m2) on day 1, while prochlorperazine and dexamethasone were administered on days 2 and 3 for control of delayed emesis." | 3.68 | Acute and delayed emesis after cisplatin-based regimen: description and prevention. ( Beaulieu, R; Courchesne, Y; Latreille, J; Letendre, F; Lorange, A; Louvet, C; Monte, M; Neemeh, JA; Pretty, HM, 1991) |
| "An oral combination of cinnarizine and lorazepam was studied for the prophylaxis of nausea and vomiting induced by strongly emetogenic cancer chemotherapy." | 3.67 | Antiemetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam. ( Senn, HJ; Wilder-Smith, CH, 1989) |
| "5 mg intravenous haloperidol in an effort to improve patient tolerance of cytotoxic chemotherapy and decrease nausea and vomiting." | 3.66 | Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. ( Coates, A; Fox, RM; Friedlander, ML; Hedley, D; Kearsley, JH; Raghavan, D; Sims, K; Tattersall, MH, 1983) |
| " Aripiprazole was dosed flexibly up to a maximum of 30 mg daily, based on tolerability and efficacy." | 2.73 | A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. ( Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA, 2008) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 2.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 2.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "Four consecutive trials were undertaken to study lorazepam at each of three dosage levels and diphenhydramine when used in combination with iv metoclopramide and dexamethasone in patients receiving cisplatin at 120 mg/m2." | 2.66 | Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. ( Clark, RA; Fiore, JJ; Gralla, RJ; Groshen, S; Kelsen, DP; Kris, MG; Tyson, LB, 1985) |
| "A double-blind crossover trial comparing lorazepam at two dosage levels with amylobarbitone supported previous reports of the effective anxiolytic action of the drug." | 2.64 | A comparison of high- and low-dose lorazepam with amylobarbitone in patients with anxiety states. ( McClelland, HA; Newell, DJ; Schapira, K, 1977) |
| " Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome." | 2.61 | Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting. ( Forest, CP; Smith, TN; Walsh, A, 2019) |
| "Vomiting was observed in 47/71 patients (66%) and 79/164 cycles (48%)." | 1.51 | Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia. ( Goldman, RD; Hasegawa, D; Kishimoto, K; Kosaka, Y; Ono, A, 2019) |
| " infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy (HDC) for peripheral blood progenitor cell (PBPC) mobilization (MOB) or prior to autologous PBPC rescue." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| "Despite this preventative treatment, nausea and/or vomiting occurred in over one-third of all the courses." | 1.28 | [Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin]. ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990) |
| "Vomiting was totally abolished in 70% of patients; in only 4% two vomiting episodes occurred." | 1.27 | Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study. ( Mughal, TI, 1983) |
| "Lorazepam, 4 mg, was evaluated in an 18-night sleep-laboratory study involving five insomniac subjects." | 1.26 | Lorazepam-efficacy, side effects, and rebound phenomena. ( Bixler, EO; Jacoby, JA; Kales, A; Scharf, MB; Schweitzer, PK, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (35.00) | 18.7374 |
| 1990's | 24 (40.00) | 18.2507 |
| 2000's | 6 (10.00) | 29.6817 |
| 2010's | 8 (13.33) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JM | 1 |
| Wilsey, MJ | 1 |
| Dhana, L | 1 |
| Lonsdale, H | 1 |
| Lewis, D | 1 |
| Blow, A | 1 |
| Tye, J | 1 |
| Hew-Butler, T | 1 |
| Ono, A | 1 |
| Kishimoto, K | 1 |
| Hasegawa, D | 1 |
| Goldman, RD | 1 |
| Kosaka, Y | 1 |
| Smith, TN | 1 |
| Walsh, A | 1 |
| Forest, CP | 1 |
| Amini, A | 1 |
| Heidari, K | 1 |
| Asadollahi, S | 1 |
| Habibi, T | 1 |
| Shahrami, A | 1 |
| Mansouri, B | 1 |
| Kariman, H | 1 |
| Fletcher, DS | 1 |
| Coyne, PJ | 1 |
| Dodson, PW | 1 |
| Parker, GG | 1 |
| Wan, W | 1 |
| Smith, TJ | 1 |
| Murray-Brown, F | 1 |
| Dorman, S | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| Szwak, K | 1 |
| Sacchetti, A | 1 |
| Buss, MK | 1 |
| Arnold, RM | 1 |
| Weschules, DJ | 1 |
| Zimbroff, DL | 1 |
| Marcus, RN | 1 |
| Manos, G | 1 |
| Stock, E | 1 |
| McQuade, RD | 1 |
| Auby, P | 1 |
| Oren, DA | 1 |
| Bleicher, J | 1 |
| Bhaskara, A | 1 |
| Huyck, T | 1 |
| Constantino, S | 1 |
| Bardia, A | 1 |
| Loprinzi, CL | 1 |
| Silberstein, PT | 1 |
| Dunn, RT | 1 |
| Stan, VA | 1 |
| Chriki, LS | 1 |
| Filkowski, MM | 1 |
| Ghaemi, SN | 1 |
| Maher, J | 1 |
| Zorzon, M | 1 |
| Cazzato, G | 1 |
| Scharf, MB | 1 |
| Kales, A | 1 |
| Bixler, EO | 1 |
| Jacoby, JA | 1 |
| Schweitzer, PK | 1 |
| Friedlander, ML | 1 |
| Kearsley, JH | 2 |
| Sims, K | 1 |
| Coates, A | 1 |
| Hedley, D | 1 |
| Raghavan, D | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Cohn, JB | 1 |
| Stoudemire, A | 1 |
| Cotanch, P | 1 |
| Laszlo, J | 1 |
| Bishop, JF | 3 |
| Olver, IN | 1 |
| Wolf, MM | 2 |
| Matthews, JP | 3 |
| Long, M | 1 |
| Bingham, J | 1 |
| Hillcoat, BL | 2 |
| Cooper, IA | 2 |
| Mughal, TI | 1 |
| McDermott, M | 1 |
| Malik, IA | 1 |
| Khan, WA | 1 |
| Qazilbash, M | 1 |
| Ata, E | 1 |
| Butt, A | 1 |
| Khan, MA | 1 |
| Misra, R | 1 |
| Agarwal, N | 1 |
| Buzdar, AU | 1 |
| Esparza, L | 1 |
| Natale, R | 1 |
| Cody, R | 1 |
| Calzone, K | 1 |
| Benson, AB | 1 |
| Sheehan, T | 1 |
| Berry, W | 1 |
| Ahn, MJ | 1 |
| Lee, JS | 1 |
| Lee, KH | 1 |
| Suh, C | 1 |
| Choi, SS | 1 |
| Kim, SH | 1 |
| Navari, RM | 2 |
| Province, WS | 1 |
| Perrine, GM | 1 |
| Kilgore, JR | 1 |
| Homesley, HD | 1 |
| Hahne, WF | 1 |
| McLees, B | 1 |
| Heck, K | 1 |
| Barrett, RJ | 1 |
| Lentz, SS | 1 |
| Woodlief, L | 1 |
| Lovelace, JV | 1 |
| Gilbert, CJ | 1 |
| Ohly, KV | 1 |
| Rosner, G | 1 |
| Peters, WP | 1 |
| Laraki, M | 1 |
| el Mouknia, M | 1 |
| Bouaguad, A | 1 |
| Idali, B | 1 |
| Benaguida, M | 1 |
| Suga, S | 2 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nishio, Y | 1 |
| Ichihara, T | 1 |
| Ichihara, S | 1 |
| Kusugami, K | 1 |
| Saito, H | 1 |
| Climent, MA | 1 |
| Palau, J | 1 |
| Ruiz, A | 1 |
| Soriano, V | 1 |
| Aznar, E | 1 |
| Olmos, T | 1 |
| Guillem, V | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Harousseau, JL | 1 |
| Zittoun, R | 1 |
| Bonneterre, J | 1 |
| Hedouin, M | 1 |
| Ouvry, J | 1 |
| Gale, G | 1 |
| Galloon, S | 1 |
| Schapira, K | 1 |
| McClelland, HA | 1 |
| Newell, DJ | 1 |
| Fürst, CJ | 1 |
| Johansson, S | 1 |
| Fredrikson, M | 1 |
| Hursti, T | 1 |
| Steineck, G | 1 |
| Peterson, C | 1 |
| Dogliotti, L | 1 |
| Antonacci, RA | 1 |
| Pazè, E | 1 |
| Ortega, C | 1 |
| Berruti, A | 1 |
| Faggiuolo, R | 1 |
| Sands, R | 1 |
| Roberts, JT | 1 |
| Marsh, M | 1 |
| Gill, A | 1 |
| Oliver, IN | 1 |
| Reynolds, S | 1 |
| Walpole, E | 1 |
| Rischin, D | 1 |
| Buchanan, L | 1 |
| Tan, LG | 1 |
| Louvet, C | 1 |
| Lorange, A | 1 |
| Letendre, F | 1 |
| Beaulieu, R | 1 |
| Pretty, HM | 1 |
| Courchesne, Y | 1 |
| Neemeh, JA | 1 |
| Monte, M | 1 |
| Latreille, J | 1 |
| Moreno, I | 1 |
| Rosell, R | 1 |
| Abad-Esteve, A | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| González Barón, M | 1 |
| Chacón, JI | 1 |
| García Girón, C | 1 |
| Ordóñez Gallego, A | 1 |
| García de Paredes, ML | 1 |
| Feliu, J | 1 |
| Zamora, P | 1 |
| Herranz, C | 1 |
| Garrido, P | 1 |
| Artal, A | 1 |
| Francom, M | 1 |
| Wilder-Smith, CH | 2 |
| Schimke, J | 1 |
| Osterwalder, B | 1 |
| Senn, HJ | 2 |
| Herrstedt, J | 1 |
| Hannibal, J | 1 |
| Hallas, J | 1 |
| Andersen, E | 1 |
| Laursen, LC | 1 |
| Hansen, M | 1 |
| Nagai, H | 1 |
| Horiuchi, Y | 1 |
| Kyokane, K | 1 |
| Miwa, Y | 1 |
| Aoki, Y | 1 |
| Yasue, K | 1 |
| Noro, T | 1 |
| Kamikawa, R | 1 |
| Ninomiya, E | 1 |
| Roila, F | 1 |
| Basurto, C | 1 |
| Bracarda, S | 1 |
| Picciafuoco, M | 1 |
| Ballatori, E | 1 |
| Del Favero, A | 1 |
| Tonato, M | 1 |
| Backonja, M | 1 |
| Beinlich, B | 1 |
| Dulli, D | 1 |
| Schutta, HS | 1 |
| Williams, AM | 1 |
| Fiumara, AM | 1 |
| Wolf, M | 1 |
| Scott, K | 1 |
| Ackland, S | 1 |
| Yuen, K | 1 |
| Morton, C | 1 |
| van Hoff, J | 1 |
| Olszewski, D | 1 |
| Craig, JB | 1 |
| Powell, BL | 1 |
| White, DR | 1 |
| Capizzi, RL | 1 |
| Briceland, LL | 1 |
| Kodama, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Arai, R | 1 |
| Tsuruta, S | 1 |
| Hayashi, S | 1 |
| Kiyota, T | 1 |
| Kris, MG | 1 |
| Gralla, RJ | 1 |
| Clark, RA | 1 |
| Tyson, LB | 1 |
| Fiore, JJ | 1 |
| Kelsen, DP | 1 |
| Groshen, S | 1 |
3 reviews available for lorazepam and Nausea
| Article | Year |
|---|---|
Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.
Topics: Acute Disease; Antiemetics; Cannabinoids; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; Vomiting | 2019 |
Haloperidol for the treatment of nausea and vomiting in palliative care patients.
Topics: Antiemetics; Diphenhydramine; Gels; Haloperidol; Humans; Lorazepam; Nausea; Palliative Care; Randomi | 2015 |
Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Behavior Therapy; Biofeedback, Psychology; Butyrophenones; Canna | 1984 |
29 trials available for lorazepam and Nausea
| Article | Year |
|---|---|
Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety.
Topics: Double-Blind Method; Female; Humans; Injections, Intravenous; Lorazepam; Male; Middle Aged; Nausea; | 2014 |
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine; | 2014 |
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dis | 2007 |
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; A | 2008 |
Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Anti-Anxiety Agents; Clinical Trials as Topic; Dizziness | 1984 |
Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1984 |
Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.
Topics: Adult; Cisplatin; Clemastine; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1995 |
Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind Method; Dru | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Drug A | 1993 |
Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neo | 1993 |
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 1995 |
[Prevention of postoperative nausea and vomiting by lorazepam].
Topics: Adult; Anti-Anxiety Agents; Humans; Lorazepam; Nausea; Placebos; Postoperative Complications; Preane | 1996 |
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 1996 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
Lorazepam as a premedication.
Topics: Adult; Anti-Anxiety Agents; Clinical Trials as Topic; Female; Humans; Lorazepam; Male; Memory; Nause | 1976 |
A comparison of high- and low-dose lorazepam with amylobarbitone in patients with anxiety states.
Topics: Adolescent; Adult; Aged; Amobarbital; Anti-Anxiety Agents; Anxiety; Clinical Trials as Topic; Drug E | 1977 |
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Indoles; Lorazepam; Male; Metoclopramide; Middl | 1992 |
A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1992 |
Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
Topics: Antiemetics; Cisplatin; Dexamethasone; Humans; Lorazepam; Metoclopramide; Nausea; Prospective Studie | 1991 |
Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
Topics: Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Methyl | 1991 |
Cinnarizine for prevention of nausea and vomiting during platin chemotherapy.
Topics: Adult; Aged; Carboplatin; Cinnarizine; Cisplatin; Combined Modality Therapy; Female; Humans; Lorazep | 1991 |
High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Droperidol; Drug Therapy, Combination; Female; Humans; | 1991 |
Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dexamethasone; Diphenhydramine; Dr | 1989 |
Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Lorazepam; Male; Methylprednisolone | 1989 |
Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1987 |
Antiemetic therapy in patients treated with high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Cytarabine; Drug Therapy, | 1987 |
[Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy].
Topics: Aged; Cisplatin; Dexamethasone; Female; Humans; Lorazepam; Lung Neoplasms; Male; Metoclopramide; Mid | 1987 |
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cisplatin; Clinical Trials as | 1985 |
28 other studies available for lorazepam and Nausea
| Article | Year |
|---|---|
Acute Treatment of Adolescent Cannabinoid Hyperemesis Syndrome With Haloperidol, Lorazepam, and/or Capsaicin: A Single Institution Case Series.
Topics: Adolescent; Adult; Cannabinoids; Capsaicin; Child; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; | 2023 |
Considering exercise-associated hyponatraemia as a continuum.
Topics: Adult; Aftercare; Anticonvulsants; Antidiuretic Agents; Confusion; Cystic Fibrosis; Deamino Arginine | 2018 |
Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineopl | 2019 |
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
Droperidol use in pediatric emergency department patients.
Topics: Adjuvants, Anesthesia; Adolescent; Anti-Anxiety Agents; Antiemetics; Central Nervous System Depressa | 2010 |
Challenges in palliative care research: one experience.
Topics: Antiemetics; Attitude of Health Personnel; Diphenhydramine; Drug Combinations; Ethics Committees, Re | 2004 |
Tolerability of the compound ABHR in hospice patients.
Topics: Aged; Antiemetics; Cohort Studies; Diphenhydramine; Drug Combinations; Female; Haloperidol; Hospice | 2005 |
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini | 2008 |
Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy.
Topics: Anti-Anxiety Agents; Antineoplastic Agents; Humans; Injections, Intravenous; Lorazepam; Nausea; Neop | 1981 |
[Side-effects and changes in systemic arterial pressure after administration of a single dose of lorazepam].
Topics: Adult; Aged; Anti-Anxiety Agents; Asthenia; Blood Pressure; Female; Humans; Lorazepam; Male; Middle | 1981 |
Lorazepam-efficacy, side effects, and rebound phenomena.
Topics: Amnesia; Anti-Anxiety Agents; Humans; Lorazepam; Nausea; Sleep Initiation and Maintenance Disorders; | 1982 |
Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy.
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Haloperi | 1983 |
Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study.
Topics: Adult; Antiemetics; Antineoplastic Agents; Drug Evaluation; Humans; Lorazepam; Lymphoma; Middle Aged | 1983 |
DAB: a three-drug combination provides alternative to 5-HT3 receptor drugs.
Topics: Antineoplastic Agents; Dexamethasone; Diphenhydramine; Drug Combinations; Humans; Lorazepam; Nausea; | 1995 |
Effective control of cisplatin induced emesis by combination drug regimen.
Topics: Adult; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Combinations; Female; Follow-Up | 1994 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; | 1998 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
Control of cisplatin induced emesis--a multidisciplinary intervention strategy.
Topics: Adult; Aged; Biperiden; Cisplatin; Female; Humans; Lorazepam; Metoclopramide; Middle Aged; Nausea; O | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Acute and delayed emesis after cisplatin-based regimen: description and prevention.
Topics: Acute Disease; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lora | 1991 |
Compounding nausea aid.
Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Comp | 1991 |
[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1990 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
Antiemetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Agents; Cinnarizine; Cisplatin; Drug Therap | 1989 |
Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches.
Topics: Adult; Dihydroergotamine; Female; Haloperidol; Humans; Lorazepam; Migraine Disorders; Nausea; Vomiti | 1989 |
Lorazepam for the control of chemotherapy-related nausea and vomiting in children.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Humans; Lorazepam; Nausea; Pilot Project | 1988 |
Lorazepam as an adjunct to antiemetic therapy in patients receiving cytotoxic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Lorazepam; Nausea; Vomiting | 1987 |
Corticosteroids and lorazepam as antiemetics in cancer chemotherapy.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Lora | 1986 |